Foamix Pharmaceuticals Ltd. Announces Upsizing and Pricing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Foamix Pharmaceuticals Ltd. Announces Upsizing and Pricing of Its $60 Million Public Offering of Ordinary Shares

REHOVOT, Israel and BRIDGEWATER, N.J., April 15, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. All of the shares are being offered by the company. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 967,741 additional ordinary shares. The offering is expected to close on Monday, April 20, 2015, subject to customary closing conditions.

Barclays Capital Inc., Cowen and Company, LLC and Guggenheim Securities, LLC are acting as book-running managers for the offering. Oppenheimer & Co. Inc. is acting as co-manager. The offering of these securities will be made only by means of a written prospectus. A copy of the prospectus related to the offering, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1 (888) 603-5847, or by emailing: Barclaysprospectus@broadridge.com ; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, fax: 631-254-7140; or Guggenheim Securities, LLC, 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, telephone: (212) 518-9349 or by emailing: GSEquityProspectusDelivery@guggenheimpartners.com .

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Foamix Pharmaceuticals Ltd.

Foamix is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix's lead product candidate, FMX101 for moderate-to-severe acne, is a novel topical foam formulation of the antibiotic minocycline. Foamix also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.

Dov Tamarkin, CEO Foamix Pharmaceuticals Ltd. +972-8-9316233 U.S. Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 7

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Purina Institute Highlights Nutritional Science at WSAVA 2026

Updated Category News Views 9

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Continue Reading
Cala Launches Game-Changer Wearable for Tremor Relief

Updated Category News Views 10

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Continue Reading
Skandia's Soundproofing Kit Expands to Brazil's Skies

Updated Category News Views 4

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

Continue Reading
Cure Blindness Project's 770K Screenings for World Sight Day

Updated Category News Views 5

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 9

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

Updated Category News Views 4

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

Continue Reading
NYSE Texas Redefines the U.S. Capital Markets Landscape

Updated Category News Views 12

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Continue Reading
Pushing for National Liver Cancer Awareness in 2026

Updated Category News Views 7

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Continue Reading
Karoo Health Leaps Forward with New CCO Breton

Updated Category News Views 8

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Continue Reading

Top 5 Most Recently Viewed Articles

Insight into Net Asset Value of Octopus AIM VCT 2 plc

Updated Category News Views 110

Understanding the Net Asset Value of Octopus AIM VCT 2 plc Octopus AIM VCT 2 plc plays a significant role in investment opportunities within the Alternative Investment Market. One of the crucial metrics for evaluating the performance of such investment trusts is the Net Asset Value (NAV). The NAV reflects the per-share value of the company’s assets after all liabilities...

Continue Reading
EPAM Recognized as Leading IT Vendor in Europe Again

Updated Category News Views 93

EPAM's New Achievement as a Top IT Vendor EPAM Systems, Inc. (NYSE: EPAM) has once again made headlines by being recognized as the top IT vendor in Europe. Celebrated for its outstanding performance across multiple categories, EPAM is acknowledged as an 'Exceptional Performer' by Whitelane Research, an independent authority known for its insights into IT sourcing in...

Continue Reading
Digital Connections: Taiwan Youths Embrace Shared Trends

Updated Category News Views 264

Exploring Cultural Connections Among Taiwan's Youth In the fast-paced world of digital communication, young people across the Taiwan Straits are connecting through a shared language and cultural roots. These ties are becoming increasingly relevant as digital interactions allow for emotional resonance through popular buzzwords. Top Buzzwords Defined by Taiwan's Youth Among...

Continue Reading
Agilysys Shareholders Endorse New Equity Plan and Directors

Updated Category News Views 104

Agilysys Shareholders Vote on Key Proposals Agilysys Inc. (NASDAQ: AGYS), a well-known provider of hospitality software solutions, recently held its annual stockholders meeting. Here, shareholders made important decisions that will shape the company's future. The meeting's agenda included the election of directors, the approval of a new equity incentive plan, an advisory...

Continue Reading
Getty Images to Share Q3 2025 Results and Details Soon

Updated Category News Views 195

Getty Images Financial Results Announcement Getty Images Holdings, Inc. (NYSE: GETY), a leading global visual content creator and marketplace, recently announced its plans to release its third quarter 2025 financial results. The company will share these results after the market closes, creating anticipation among investors and stakeholders regarding its performance....

Continue Reading